A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Eculizumab (SOLIRIS)

Eculizumab blocks complement system activation to treat rare blood and immune disorders.

First FDA approval2007-04-02
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$273.2M in CY2024 Part D spend6K claims · 714 beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Eculizumab used for?

Eculizumab blocks complement system activation to treat rare blood and immune disorders.

Is there a generic for Eculizumab?

No. Eculizumab is brand-only with no generic equivalents currently in market.

How much does my plan pay for Eculizumab?

NADAC pricing data not currently available for this drug.

Is Eculizumab on the FDA shortage list?

No. Eculizumab is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Complement Inhibitor6 alternatives in D1
01
Eculizumab-Aagh
Brand: EPYSQLI
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
02
Eculizumab-Aeeb
Brand: BKEMV
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
03
Pegcetacoplan
Brand: Empaveli
Lowest NADAC
0Generic mfrs
$41.1MCY24 Part D spend
Compare →
04
Pozelimab
Brand: VEOPOZ
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
05
Ravulizumab
Brand: Ultomiris
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
06
Zilucoplan
Brand: ZILBRYSQ
Lowest NADAC
0Generic mfrs
$90.6MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.